The 2022 HF with reduced ejection fraction (HFrEF) therapy recommendations [3] call for the rapid initiation of four types of medications for HFrEF, including “novel” (SGLT2 inhibitors and SAC/VAL) and more traditional agents (ACEi/ARB, beta blockers and MRA). The gene discussed is SLC5A2; the disease is hydrops fetalis.